CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk

Cancer Research

Volumn 61, Issue 9, 2001, Pages 3566-3569

  Bigler, J ^a   Whitton, J ^a   Lampe, J W ^a   Fosdick, L ^a   Bostick, R M ^a   Potter, J D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A6; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; COLON ADENOMA; CONTROLLED STUDY; ENZYME METABOLISM; GENE ISOLATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; INCIDENCE; INTESTINE EPITHELIUM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADENOMA; ADENOMATOUS POLYPS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0035328829     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. A genetic model for colorectal tumorigenesis
2. Nonsteroidal anti-inflammatory drugs and cancer prevention
3. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
4. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
5. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
6. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
7. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer
8. Mechanisms of action: Aspirin
9. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2
10. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
11. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
12. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
13. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms
14. Coordinate up-regulation of low-density lipoprotein receptor and cyclooxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies
15. Differential expression of cyclooxygenase-2 in human colorectal cancer
16. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
17. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis
18. 2 in human colon cancer cells
19. Aspirin: Plasma concentration and effects
20. The metabolism of aspirin in man: A population study
21. 359 variants: Enzyme kinetic study with seven substrates
22. Cytochrome P450 2C9: An enzyme of major importance in human drug metabolism
23. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: Pharmacological implications
24. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
25. 359 allelic variant in the tolbutamide polymorphism
26. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation
27. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
28. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County
29. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
30. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
31. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
32. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: Relationships to serum bilirubin concentrations
33. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: The Minnesota Cancer Prevention Research Unit Case-Control Study
34. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenoma
35. Determination of human NAT2 acetylator genotype by oligonucleotide ligation assay
36. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity
37. Hydroxylation of salicylate by microsomal fractions and cytochrome P-450. Lack of production of 2,3-dihydroxybenzoate unless hydroxyl radical formation is permitted
38. Suppression of inducible cyclooxygenase-2 gene transcription by aspirin and sodium salicylate
39. 2 synthesis in murine macrophages
40. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines
41. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects
42. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benenesulfonamide (SC-58635, celecoxib)
43. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor